1. Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute of Allergy and Infectious Diseases NIH/DHHS

6. NIAID Centers of Excellence for Influenza Research and Surveillance Goal Goal: To carry out an international and/or domestic animal surveillance program with emphasis on the rapid characterization of influenza viruses with pandemic potential; to carry out a research program to determine the factors that influence influenza viruses, and characterize the immune response to influenza infection and/or vaccination. BAA was announced October 18, 2005 BAA was announced October 18, 2005 Applications were due March 6, 2006 Applications were due March 6, 2006 Review is ongoing Review is ongoing Awards anticipated in December 2006 Awards anticipated in December 2006 Goal Goal: To carry out an international and/or domestic animal surveillance program with emphasis on the rapid characterization of influenza viruses with pandemic potential; to carry out a research program to determine the factors that influence influenza viruses, and characterize the immune response to influenza infection and/or vaccination. BAA was announced October 18, 2005 BAA was announced October 18, 2005 Applications were due March 6, 2006 Applications were due March 6, 2006 Review is ongoing Review is ongoing Awards anticipated in December 2006 Awards anticipated in December 2006

8. NIAID Influenza Diagnostics-Examples Emerging Diagnostic Technologies Advanced/Later Stage Product Development Applied/Early Stage Product Dev Multiplex Immunoassay Platform for Respiratory Viruses Multiplex PCR Detection Platform for Respiratory Viruses DNA/RNA Multiplex Platform/Chip for Influenza Detection and Subtyping Proteomics/Protein Diagnostic Arrays Nanotechnology Multiplex PCR-Mass Spectrometry Platform for Respiratory Viruses

13. H5N1 Vaccine Trials: Strategies to Enhance Immunogenicity Route: ID vs. IM administration Route: ID vs. IM administration Give a 3 rd dose of vaccine at 6 months Give a 3 rd dose of vaccine at 6 months Adult study completed Adult study completed Evaluate adjuvants Evaluate adjuvants H5N1 (sanofi) with and without AlOH H5N1 (sanofi) with and without AlOH H5N1 (Novartis) with and without AlOH or MF59 H5N1 (Novartis) with and without AlOH or MF59 H5N1 (Baxter-cell culture) with and without AlOH H5N1 (Baxter-cell culture) with and without AlOH Route: ID vs. IM administration Route: ID vs. IM administration Give a 3 rd dose of vaccine at 6 months Give a 3 rd dose of vaccine at 6 months Adult study completed Adult study completed Evaluate adjuvants Evaluate adjuvants H5N1 (sanofi) with and without AlOH H5N1 (sanofi) with and without AlOH H5N1 (Novartis) with and without AlOH or MF59 H5N1 (Novartis) with and without AlOH or MF59 H5N1 (Baxter-cell culture) with and without AlOH H5N1 (Baxter-cell culture) with and without AlOH